行情

ZIOP

ZIOP

ZIOPHARM肿瘤
NASDAQ

实时行情|Nasdaq Last Sale

4.485
-0.065
-1.43%
交易中 12:47 11/14 EST
开盘
4.520
昨收
4.550
最高
4.650
最低
4.435
成交量
47.95万
成交额
--
52周最高
7.25
52周最低
1.560
市值
8.12亿
市盈率(TTM)
6.66
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZIOP 新闻

  • Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast
  • GlobeNewswire.3天前
  • ZIOPHARM Oncology, Inc. (ZIOP) CEO Dr. Laurence Cooper on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.3天前
  • Ziopharm Oncology Inc (ZIOP) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.6天前
  • Edited Transcript of ZIOP earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.6天前

更多

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
-0.55%

热门股票

名称
价格
涨跌幅

ZIOP 简况

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
展开

Webull提供ZIOPHARM Oncology Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。